Kevin Young - Net Worth and Insider Trading
Kevin Young Net Worth
The estimated net worth of Kevin Young is at least $21 Million dollars as of 2024-11-09. Kevin Young is the EVP, Commercial Operations of Gilead Sciences Inc and owns about 216,418 shares of Gilead Sciences Inc (GILD) stock worth over $21 Million. Kevin Young is also the Director of Quince Therapeutics Inc and owns about 30,000 shares of Quince Therapeutics Inc (QNCX) stock worth over $51,000. Details can be seen in Kevin Young's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Kevin Young has not made any transactions after 2019-05-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Kevin Young
Kevin Young Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Kevin Young owns 2 companies in total, including Quince Therapeutics Inc (QNCX) , and Gilead Sciences Inc (GILD) .
Click here to see the complete history of Kevin Young’s form 4 insider trades.
Insider Ownership Summary of Kevin Young
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| QNCX | Quince Therapeutics Inc | 2019-05-13 | director |
| GILD | Gilead Sciences Inc | 2016-05-24 | Chief Operating Officer |
Kevin Young Latest Holdings Summary
Kevin Young currently owns a total of 2 stocks. Among these stocks, Kevin Young owns 216,418 shares of Gilead Sciences Inc (GILD) as of January 23, 2014, with a value of $21 Million and a weighting of 99.76%. Kevin Young also owns 30,000 shares of Quince Therapeutics Inc (QNCX) as of May 13, 2019, with a value of $51,000 and a weighting of 0.24%.
Latest Holdings of Kevin Young
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| GILD | Gilead Sciences Inc | 2014-01-23 | 216,418 | 96.57 | 20,898,404 |
| QNCX | Quince Therapeutics Inc | 2019-05-13 | 30,000 | 1.70 | 51,000 |
Holding Weightings of Kevin Young
Kevin Young Form 4 Trading Tracker
According to the SEC Form 4 filings, Kevin Young has made a total of 0 transactions in Gilead Sciences Inc (GILD) over the past 5 years. The most-recent trade in Gilead Sciences Inc is the sale of 100,000 shares on January 23, 2014, which brought Kevin Young around $8 Million.
According to the SEC Form 4 filings, Kevin Young has made a total of 0 transactions in Quince Therapeutics Inc (QNCX) over the past 5 years. The most-recent trade in Quince Therapeutics Inc is the acquisition of 30,000 shares on May 13, 2019, which cost Kevin Young around $510,000.
Insider Trading History of Kevin Young
- 1
Kevin Young Trading Performance
GuruFocus tracks the stock performance after each of Kevin Young's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Kevin Young is 24.52%. GuruFocus also compares Kevin Young's trading performance to market benchmark return within the same time period. The performance of stocks bought by Kevin Young within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Kevin Young's insider trading performs compared to the benchmark.
Performance of Kevin Young
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 31.46 | | | | | |
| Relative Return to S&P 500(%) | 28.62 | | | | | |
Kevin Young Ownership Network
Ownership Network List of Kevin Young
Ownership Network Relation of Kevin Young
Kevin Young Owned Company Details
What does Quince Therapeutics Inc do?
Who are the key executives at Quince Therapeutics Inc?
Kevin Young is the director of Quince Therapeutics Inc. Other key executives at Quince Therapeutics Inc include director & Chief Executive Officer Dirk Thye , Chief Business Officer Brendan Hannah , and President Charles S. Ryan .
Quince Therapeutics Inc (QNCX) Insider Trades Summary
Over the past 18 months, Kevin Young made no insider transaction in Quince Therapeutics Inc (QNCX). Other recent insider transactions involving Quince Therapeutics Inc (QNCX) include a net purchase of 500,436 shares made by David Lamond , a net purchase of 322,500 shares made by Dirk Thye , and a net purchase of 110,686 shares made by Brendan Hannah .
In summary, during the past 3 months, insiders sold 0 shares of Quince Therapeutics Inc (QNCX) in total and bought 241,811 shares, with a net purchase of 241,811 shares. During the past 18 months, 0 shares of Quince Therapeutics Inc (QNCX) were sold and 990,009 shares were bought by its insiders, resulting in a net purchase of 990,009 shares.
Quince Therapeutics Inc (QNCX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Quince Therapeutics Inc Insider Transactions
Kevin Young Mailing Address
Above is the net worth, insider trading, and ownership report for Kevin Young. You might contact Kevin Young via mailing address: Gilead Sciences, Inc., 333 Lakeside Drive, Foster City Ca 94015.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
